AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8506782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy in women
Number of subjects: 64
Study 8506782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption in both men and women
Number of subjects: 64
Study 8506782 — intervention group
Group type: COMPARATOR
Intervention: Control for beliefs
Number of subjects: 64
Study 8506782 — intervention group
Group type: COMPARATOR
Intervention: Alcohol expectancy in men
Number of subjects: 64
Study 3090603 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills intervention group
Number of subjects: 1281
Study 3090603 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion intervention group
Number of subjects: 1281
Study 3090603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1281
Study 29544905 — intervention group
Group type: EXPERIMENTAL
Intervention: CellScope Oto® smartphone device
Number of subjects: 94
Study 29544905 — intervention group
Group type: COMPARATOR
Intervention: Traditional otoscope
Number of subjects: 94
Study 29544905 — intervention group
Group type: COMPARATOR
Intervention: Control exam by treating physician
Number of subjects: 94
Study 29544905 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental preference
Number of subjects: 94
Study 27272076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost plus mometasone
Number of subjects: 32
Study 27272076 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost monotherapy
Number of subjects: 32
Study 27272076 — intervention group
Group type: COMPARATOR
Intervention: Mometasone plus placebo
Number of subjects: 32
Study 24401214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive rosuvastatin therapy (achieve 30% lower LDL-C levels than standard)
Number of subjects: 60
Study 24401214 — intervention group
Group type: COMPARATOR
Intervention: Standard rosuvastatin therapy (achieve LDL-C levels recommended by Japanese guidelines)
Number of subjects: 60
Study 23521655 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.02 mg.kg(‐1)) and propofol infusion (1.0 μg.ml(‐1) effect-site concentration)
Number of subjects: 20
Study 23521655 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil administration
Number of subjects: 20
Study 21177169 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg) every night for 3 months in HLT and NLT groups
Number of subjects: 85
Study 21177169 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months in HLC and NLC groups
Number of subjects: 85
Study 17996239 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Parenting Program (12-week duration)
Number of subjects: 29
Study 17996239 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study 16008604 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with tacrolimus
Number of subjects: 0
Study 16008604 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with cyclosporine microemulsion
Number of subjects: 0
Study 14576764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (exact dosage not specified)
Number of subjects: 168
Study 10553392 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg, 24-hour nicotine patch therapy (active patch)
Number of subjects: 958
Study 10553392 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 958
Study 10553392 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-mg, 24-hour nicotine patch therapy (open label-pay)
Number of subjects: 958
Study 10553392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in comparison with open label-pay)
Number of subjects: 958
Study 8647491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mononuclear cells from umbilical blood
Number of subjects: 31
Study 2066891 — intervention group
Group type: EXPERIMENTAL
Intervention: Material A
Number of subjects: 14
Study 2066891 — intervention group
Group type: EXPERIMENTAL
Intervention: Material B
Number of subjects: 14
Study 6683539 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule (100 mg)
Number of subjects: 12
Study 6683539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (100 mg)
Number of subjects: 12
Study 6683539 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (100 mg)
Number of subjects: 12
Study 6683539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets (150 mg, 300 mg, 600 mg)
Number of subjects: 12
Study 31771448 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured pre-simulation preparation and briefing (35 minutes)
Number of subjects: 80
Study 31771448 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation and briefing
Number of subjects: 80
Study 30170568 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single-fraction 24 Gy
Number of subjects: 55
Study 30170568 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) - 30 Gy/10 fractions
Number of subjects: 55
Study 26911262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (up to three nutritional sessions conducted by a bilingual dietitian)
Number of subjects: 18
Study 24246768 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (1 × 10(8) colony‐forming units, 3 times daily; n = 86)
Number of subjects: 160
Study 24246768 — intervention group
Group type: COMPARATOR
Intervention: No test article (control; n = 74)
Number of subjects: 160
Study 24246768 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 160
Study 24246768 — intervention group
Group type: COMPARATOR
Intervention: No test article (control)
Number of subjects: 160
Study 22561055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB) 1 mg twice daily for 8 weeks
Number of subjects: 25
Study 22561055 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide (NEB) 1 mg twice daily for 8 weeks
Number of subjects: 25
Study 22561055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB)
Number of subjects: 25
Study 18632181 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly docetaxel (33.3 mg/m² on days 1, 8, 15 q 4 weeks)
Number of subjects: 84
Study 18632181 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (30 mg/m² on days 1, 8, 15) plus gemcitabine (800 mg/m² on days 1, 8 q 4 weeks) or plus vinorelbine (20 mg/m² on days 1, 8 q 4 weeks)
Number of subjects: 84
Study 18632181 — intervention group
Group type: COMPARATOR
Intervention: Weekly docetaxel (as in arm B) plus capecitabine (625 mg/m² twice daily on days 5-18 q 4 weeks)
Number of subjects: 84
Study 16907846 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg 400 IU intramuscularly once a month at the third, second and first month before delivery
Number of subjects: 250
Study 16907846 — intervention group
Group type: COMPARATOR
Intervention: No antepartum treatment
Number of subjects: 250
Study 16907846 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg 400 IU intramuscularly
Number of subjects: 250
Study 14691614 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (600 mg daily except 200 mg daily for the first 2 days)
Number of subjects: 12
Study 11297908 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine nasal spray (0.2%)
Number of subjects: 0
Study 11297908 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate
Number of subjects: 0
Study 11297908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9550476 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (50 microg orally twice daily)
Number of subjects: 308
Study 9550476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 7909209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 40
Study 7909209 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40
Study 3076492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (10 mg b.d.)
Number of subjects: 0
Study 3076492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31344528 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 1037
Study 28733813 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cannabis
Number of subjects: 24
Study 28733813 — intervention group
Group type: COMPARATOR
Intervention: Active tobacco
Number of subjects: 24
Study 28733813 — intervention group
Group type: COMPARATOR
Intervention: Placebo cannabis
Number of subjects: 24
Study 28733813 — intervention group
Group type: COMPARATOR
Intervention: Placebo tobacco
Number of subjects: 24
Study 25626575 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Heart EXCOR
Number of subjects: 0
Study 25626575 — intervention group
Group type: COMPARATOR
Intervention: Infant Jarvik 2000
Number of subjects: 0
Study 23497020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented turmeric powder (FTP) 3.0 g per day for 12 weeks
Number of subjects: 60
Study 23497020 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3.0 g per day for 12 weeks
Number of subjects: 60
Study 21476202 — intervention group
Group type: EXPERIMENTAL
Intervention: Real Acupuncture (RA) at Hegu (LI4) and Sanyinjiao (SP6) points
Number of subjects: 38
Study 21476202 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture (SA)
Number of subjects: 38
Study 17875549 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of omega-3-polyunsaturated fatty acids
Number of subjects: 60
Study 14735648 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 hours of bed rest (experimental group)
Number of subjects: 68
Study 14735648 — intervention group
Group type: COMPARATOR
Intervention: 4 hours of bed rest (control group)
Number of subjects: 68
Study 12409561 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 9824785 — intervention group
Group type: EXPERIMENTAL
Intervention: K4MgCit2 (49 mEq K, 25 mEq Mg, and 74 mEq citrate/day)
Number of subjects: 62
Study 9824785 — intervention group
Group type: EXPERIMENTAL
Intervention: K3MgHCit2 (49 mEq K, 33 mEq Mg, and 98 mEq citrate/day)
Number of subjects: 62
Study 9824785 — intervention group
Group type: EXPERIMENTAL
Intervention: K5MgCit2Cl (49 mEq K, 20 mEq Mg, 10 mEq Cl and 59 mEq citrate/day)
Number of subjects: 62
Study 7661060 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (53% of patients treated with a thrombolytic agent in 1992)
Number of subjects: 0
Study 7661060 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no thrombolytic therapy in 1966 and 1981-1983)
Number of subjects: 0
Study 2757244 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol 5 micrograms iv
Number of subjects: 20
Study 2757244 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS group; n = 10)
Number of subjects: 20
Study 6815 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of ipecac orally
Number of subjects: 28
Study 6815 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg/kg apomorphine subcutaneously
Number of subjects: 28
Study 31028971 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian wet cupping technique
Number of subjects: 70
Study 31028971 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Hijamah technique
Number of subjects: 70
Study 28377403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid flow expulsion maneuver
Number of subjects: 16
Study 25632066 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐GEMOX (500 mg/m² cetuximab plus GEMOX: 800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Number of subjects: 122
Study 25632066 — intervention group
Group type: COMPARATOR
Intervention: GEMOX (800 mg/m² gemcitabine and 85 mg/m² oxaliplatin) every 2 weeks
Number of subjects: 122
Study 23442047 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed-cisplatin
Number of subjects: 111
Study 23442047 — intervention group
Group type: COMPARATOR
Intervention: Placebo-cisplatin
Number of subjects: 111
Study 21613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (n = 21)
Number of subjects: 42
Study 21613792 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment without inhibitors of the renin-angiotensin-aldosterone system (n = 21)
Number of subjects: 42
Study 21613792 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 20)
Number of subjects: 42
Study 19661125 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 22
Study 19661125 — intervention group
Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 22
Study 16953530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (morphine 5 mg at time zero and 5 mg at 20 minutes, ketorolac 15 mg at time zero and 15 mg at 20 minutes)
Number of subjects: 130
Study 16953530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 130
Study 16953530 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone (5 mg at time zero and 5 mg at 20 minutes)
Number of subjects: 130
Study 16953530 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac alone (15 mg at time zero and 15 mg at 20 minutes)
Number of subjects: 130
Study 14764773 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily for 2 years
Number of subjects: 90
Study 14764773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol plus 1 mg norethisterone acetate daily for 2 years (HRT)
Number of subjects: 90
Study 14764773 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alendronate and HRT for 2 years
Number of subjects: 90
Study 11590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat ω-5 gliadin IgE antibody testing
Number of subjects: 40
Study 11590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral wheat challenge
Number of subjects: 40
Study 11590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick testing with ω-5 gliadin
Number of subjects: 40
Study 11590393 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with no evidence of food allergies)
Number of subjects: 40
Study 11590393 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat ω-5 gliadin ELISA
Number of subjects: 40
Study 9220180 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 9220180 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 21
Study 8360063 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program using transtelephonic exercise monitoring (TEM) for 12 weeks, training 3 days per week for a maximum of 35 minutes at 75% of maximum heart rate reserve.
Number of subjects: 20
Study 8360063 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based exercise program for 12 weeks, training 3 days per week for a maximum of 35 minutes at 75% of maximum heart rate reserve.
Number of subjects: 20
Study 3312625 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg/kg methylprednisolone (steroid-treated)
Number of subjects: 82
Study 3312625 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 31547713 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy in children
Number of subjects: 149
Study 31547713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy in children
Number of subjects: 149
Study 31547713 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional immunotherapy in adults
Number of subjects: 149
Study 31547713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster immunotherapy in adults
Number of subjects: 149
Study 31547713 — intervention group
Group type: COMPARATOR
Intervention: All groups (conventional and cluster)
Number of subjects: 149
Study 29496605 — intervention group
Group type: EXPERIMENTAL
Intervention: RVA pacing
Number of subjects: 63
Study 29496605 — intervention group
Group type: EXPERIMENTAL
Intervention: RVS pacing
Number of subjects: 63
Study 29496605 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-CS pacing
Number of subjects: 63
Study 29496605 — intervention group
Group type: COMPARATOR
Intervention: RVA-ICD
Number of subjects: 63
Study 29496605 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular leads
Number of subjects: 63
Study 29496605 — intervention group
Group type: EXPERIMENTAL
Intervention: LV-CS leads
Number of subjects: 63
Study 27647770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormeloxifene (60 mg twice per week)
Number of subjects: 50
Study 27647770 — intervention group
Group type: COMPARATOR
Intervention: Combined Oral Contraceptive (ethinyl estradiol 30 μg with desogestrel 150 μg on days 1-21 for 6 months)
Number of subjects: 50
Study 27647770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 24188122 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLBs)
Number of subjects: 46
Study 24188122 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets (CBs)
Number of subjects: 46
Study 23059433 — intervention group
Group type: EXPERIMENTAL
Intervention: Active reflexology treatment to areas of the feet corresponding to the heart
Number of subjects: 16
Study 23059433 — intervention group
Group type: COMPARATOR
Intervention: Control reflexology treatment to other areas of the feet
Number of subjects: 16
Study 20212250 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with sorafenib (arm A)
Number of subjects: 926
Study 20212250 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel with placebo (arm B)
Number of subjects: 926
Study 18493254 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised anaesthesia delivery system (Wand)
Number of subjects: 147
Study 18493254 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 147
Study 18493254 — intervention group
Group type: EXPERIMENTAL
Intervention: High dental anxiety
Number of subjects: 147
Study 18493254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dental anxiety
Number of subjects: 147
Study 15747811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular banded premolar anchorage (group A)
Number of subjects: 87
Study 15747811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular banded premolar-molar anchorage (group B)
Number of subjects: 87
Study 15747811 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular cast splint anchorage (group D)
Number of subjects: 87
Study 15747811 — intervention group
Group type: COMPARATOR
Intervention: Cast splint anchorage in Class II:1 and Class II:2 cases
Number of subjects: 87
Study 15747811 — intervention group
Group type: EXPERIMENTAL
Intervention: All three anchorage forms
Number of subjects: 87
Study 11960019 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological motion stimulus based on a limited lifetime technique
Number of subjects: 0
Study 11960019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks involving the discrimination of walking direction or the coherence of a walking figure
Number of subjects: 0
Study 10618885 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 221
Study 10618885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding
Number of subjects: 221
Study 10618885 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing mixed/formula feeding
Number of subjects: 221
Study 10618885 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal plan for exclusive breast-feeding
Number of subjects: 221
Study 10618885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding in hospital
Number of subjects: 221
Study 7790785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, unilateral 'diversified,' high velocity, low amplitude, rotatory thrust technique
Number of subjects: 50
Study 2089969 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-coated catheter (H catheter)
Number of subjects: 266
Study 2089969 — intervention group
Group type: COMPARATOR
Intervention: Silicone-coated catheter (S catheter)
Number of subjects: 266
Study 10239544 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-abortion script transcription
Number of subjects: 0
Study 10239544 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude-congruent script transcription
Number of subjects: 0
Study 31291863 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (group 2)
Number of subjects: 54
Study 31291863 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (group 1)
Number of subjects: 54
Study 29040268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (goal systolic pressure < 120 mm Hg)
Number of subjects: 14067
Study 25381189 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 36
Study 25381189 — intervention group
Group type: EXPERIMENTAL
Intervention: Companionship
Number of subjects: 36
Study 25381189 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 36
Study 23563218 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 23
Study 23563218 — intervention group
Group type: COMPARATOR
Intervention: Control group (supportive therapy)
Number of subjects: 23
Study 21440734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rabbit antithymocyte globulin (LoD-rATG, 3-5 mg/kg)
Number of subjects: 0
Study 21440734 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of rabbit antithymocyte globulin (7-10 mg/kg)
Number of subjects: 0
Study 19627671 — intervention group
Group type: EXPERIMENTAL
Intervention: Wand computer controlled local analgesia (LA) system
Number of subjects: 38
Study 19627671 — intervention group
Group type: COMPARATOR
Intervention: Conventional LA technique
Number of subjects: 38
Study 16909140 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus irinotecan (IG) - 300 mg m(‐2) on day 8, gemcitabine on days 1 and 8, repeated every 3 weeks.
Number of subjects: 145
Study 16909140 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (G) - 900 mg m(‐2) on days 1, 8, and 15 every 4 weeks.
Number of subjects: 145
Study 15294399 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular cooling to a target temperature of 33 degrees C for 24 hours using the CoolGard System and Icy catheter.
Number of subjects: 13
Study 11426345 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy cream (testosterone 0.8%, isosorbide dinitrate 0.5%, co‐dergocrine mesylate 0.06%)
Number of subjects: 42